Regeneron Pharmaceuticals achieved positive results for EYLEA (aflibercept) Injection from the Phase III VIBRANT study in patients with Macular Edema following Branch Retinal Vein Occlusion (BRVO). In the trial, 53% of patients who received EYLEA 2 milligram every four weeks gained at least 15 letters in vision from baseline at week 24, the primary endpoint of the study, compared to 27% of patients who received laser, a standard-of-care treatment.   The incidence of serious adverse events (SAE) ...